In light of recently implemented HPV vaccination programs to prevent cervical disease, public health programs are developing strategies for measuring vaccine impact. In addition to monitoring vaccine utilization, states are able to initiate surveillance for behavioral and disease outcomes.
We will present a variety of innovative surveillance projects ongoing in various parts of the United States. In particular, New Mexico is developing an integrated laboratory-based systems for collecting Pap, pathology, and HPV test results; Florida requires electronic reporting of all abnormal cervical cytology and histology, high risk HPV infections, respiratory papillomatosis (age 0-6 years), and anogenital HPV in children less than 12 years of age; Connecticut and California are establishing demonstration projects through the Emerging Infections Program to monitor the incidence of pre-cancerous cervical disease. Behavioral surveillance activities for assessing trends in vaccine uptake and Pap utilization will also be presented. In addition, there will be an opportunity to discuss immunization and cancer registries and how they interface with other health data systems. The presentations and subsequent discussion will clarify the value and feasibility of various strategies and generate ideas for collaboration and expansion.
Methods (instructional approach):
Each presentation of existing successful projects will include a description of the system; the methods used to implement new surveillance tools; an assessment of the feasibility and costs; the barriers encountered; preliminary results; and future plans. Participants will have the opportunity to ask questions and receive technical assistance in trouble-shooting challenges anticipated for their own jurisdiction.